ReviewClinical ophthalmology (Auckland, N.Z.)2018
Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.
Review in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Pooled it
- Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.Advances in therapy · 2020Trial
- Preparation of a new fixed-combination carteolol-netarsudil ophthalmic solution via one-pot pH-adjusting solubilization strategy for glaucoma treatment.Drug delivery · 2026Article
- Promising Glaucoma Medication: A Comprehensive Translational Evaluation.Pharmaceutics · 2026Article
- New trends in the treatment of open-angle glaucoma: a critical review.International ophthalmology · 2025Review
- A Comprehensive Review of the Role of Rho-Kinase Inhibitors in Corneal Diseases.Life (Basel, Switzerland) · 2025Review
- A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS).BMC pharmacology & toxicology · 2025Article
- Crystalline keratopathy following long-term netarsudil therapy.American journal of ophthalmology case reports · 2024Article
- Characterization of Forced Degradation Products of Netarsudil: Optimization and Validation of a Stability-Indicating RP-HPLC Method for Simultaneous Quantification of Process-Related Impurities.Turkish journal of pharmaceutical sciences · 2024Article
- Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy.Ophthalmology and therapy · 2023Review
- Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Two pediatric cases of reticular corneal epithelial edema associated with netarsudil.American journal of ophthalmology case reports · 2022Article
- Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center.Indian journal of ophthalmology · 2022Article
- Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect.Journal of ophthalmology · 2022Article
- Review
- [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- A tissue-engineered human trabecular meshwork hydrogel for advanced glaucoma disease modeling.Experimental eye research · 2021Article
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.Eye (London, England) · 2020Review
- A Case Report Illustrating the Postoperative Course of Descemetorhexis without Endothelial Keratoplasty with Topical Netarsudil Therapy.Case reports in ophthalmological medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials. It has been shown to be noninferior to the therapy with topical timolol in individuals with baseline IOP <25 mmHg. Importantly, netarsudil has been shown to reduce IOP to the same degree, regardless of baseline levels. There are no known systemic safety issues associated with netarsudil. The most common local adverse effects relate to conjunctival hyperemia. The once-daily dosing schedule is advantageous for individuals who have difficulties with medication adherence. Further studies of a combination of netarsudil and latanoprost agents are currently underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.